OR WAIT null SECS
April 01, 2016
At DCAT's annual meeting, Bill Downey, president of the market research firm High Tech Business Decisions, summarized results from its latest survey on biopharmaceutical outsourcing.
March 24, 2016
Collaboration will provide for unified development and manufacture of antibody drug conjugates.
November 23, 2015
The University of Sheffield has appointed Cobra Biologics to advance novel fusion protein technology into Phase 1 clinical trials.
November 20, 2015
Expansions at Catalent’s Kansas City, MO, and Madison, WI facilities made in response to industry demand.
September 24, 2015
Cobra Biologics and the University of Manchester announce a collaboration to improve industrial scale-up of mammalian cell bioprocessing.
August 26, 2015
Recipharm will be responsible for the supply of the remaining clinical-trial material and ongoing future commercial supply of RHB-105, the lead drug candidate developed by RedHill for the treatment of Helicobacter pylori bacterial infection.
August 25, 2015
Cytovance Biologics anticipates continued expansion plans following acquisition by Hepalink USA
August 13, 2015
CMC Biologics will manufacture monoclonal antibodies (mAbs) and provide process development services for the PATH Malaria Vaccine Initiative.
August 12, 2015
Catalent selects advisory board members to complement Redwood Bioscience Scientific Advisory Board.
July 01, 2015
Gil Roth, Founder and President of the Pharma & Biopharma Outsourcing Association speaks with Pharmaceutical Technology.